Private Information About Doxorubicin Made Available

Just recently, USRDS data were published confirming that the risk of NODAT increased with sirolimus, either when used together with a CNI or with an antiproliferative agent (MMF or azathioprine) [53]. Everolimus is less investigated, but has also been associated with NODAT [54]. The fusion protein and co-stimulation blocker belatacept has been introduced in recent years and has been shown to be associated with less metabolic risk profile including less development of NODAT compared with CsA [55]. Cardiovascular events are frequent in NODAT patients [4, 5, 56-59]. Some studies even show that http://www.selleckchem.com/products/obeticholic-acid.html NODAT is associated with a two- to threefold increased risk of cardiovascular disease (CVD) and death [5, 56, 58, 59]. NODAT is defined by blood sugar criteria, but it carries important additional cardiovascular risk factors of modifiable and nonmodifiable nature, such as age, overweight, hypertension and dyslipidaemia [57]. However, even after correction for these risk factors, NODAT remains an independent risk factor for cardiovascular events. The prevalence of hypertension is increased after kidney transplantation. After the introduction http://www.selleck.cn/products/LY294002.html of CNI, up to 50�C90% of kidney transplant recipients are hypertensive [60]. The target of blood pressure after kidney transplantation should be http://www.selleckchem.com/products/Adriamycin.html Pharmacological monotherapy achieves blood pressure target only in a limited number of patients. Consequently, a combination of multiple drugs is most often required. There is no consensus about first-line therapy, and the most widely used drugs are diuretics, calcium channel blockers, beta-blockers, ACE-inhibitors and angiotensin II receptor blockers. The use of renin-angiotensin system blockade is shown to be reno- and cardioprotective in a diabetic population and the use of these agents in transplantation is now more frequent than in the past [62]. In the general population, large randomized controlled trials have shown strong evidence that reduction in low-density lipoprotein (LDL) cholesterol decreases CVD. In the transplant population, the prevalence of hyperlipidaemia is high, partly because of immunosuppressive medication.